Clinical Trial Detail

NCT ID NCT02178436
Title Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Barbara Ann Karmanos Cancer Institute
Indications

pancreatic adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel + Selinexor

Age Groups: adult

No variant requirements are available.